Chemomab Therapeutics (CMMB) Cash from Investing Activities Growth (1y) (2018 - 2023)
Chemomab Therapeutics (CMMB) Cash from Investing Activities Growth (1y) (2018 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 62.68% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -674.01% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -166.24% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Chemomab Therapeutics | 729.63 Mn | 719.26 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -81.56% |
| Sep 30, 2023 | -34.29% |
| Jun 30, 2023 | -347.13% |
| Mar 31, 2023 | 505.88% |
| Dec 31, 2022 | 147.75% |
| Sep 30, 2022 | 221.48% |
| Jun 30, 2022 | 108.38% |
| Mar 31, 2022 | 119,200.00% |
| Dec 31, 2021 | -652,600.00% |
| Sep 30, 2021 | -24,900.00% |
| Jun 30, 2021 | -70,944.83% |
| Mar 31, 2021 | 80.00% |
| Dec 31, 2020 | -101.20% |
| Sep 30, 2020 | 92.16% |
| Jun 30, 2020 | -81.25% |
| Mar 31, 2020 | 86.67% |
| Dec 31, 2019 | 1,065.38% |
| Sep 30, 2019 | -65.58% |
| Jun 30, 2019 | 70.37% |
| Mar 31, 2019 | 27.88% |